Medifast reconfirms $270M-$300M 2026 revenue outlook as it targets profitability improvements starting in Q4 2026
Medifast (NYSE: MED) reconfirmed its 2026 revenue outlook in the range of $270 million to $300 million. The company expects improvements in profitability to begin in Q4 2026. This announcement highlights Medifast's strategic focus on financial recovery and stabilization.
Citadel reports 6.5% stake in MEDIFAST (MED) in joint Schedule 13G
Entities affiliated with Citadel and Kenneth Griffin have jointly filed a Schedule 13G, disclosing a 6.5% beneficial ownership stake in MEDIFAST (MED). The filing indicates that Citadel entities and Kenneth Griffin may be deemed to beneficially own 715,910 shares of Common Stock, representing 6.5% of the class based on 11,031,693 outstanding shares as of March 23, 2026. The reported ownership includes shared voting and dispositive power rather than sole control, with Citadel Securities LLC reporting 712,864 shares.
MED | Medifast, Inc. Financials - Income Statement
This page provides financial information for Medifast, Inc. (MED), focusing on its income statement and other related financial data. It also includes details on congressional trading, insider trading activity, institutional ownership, corporate lobbying, and analyst ratings for MED. The article highlights Medifast's business model as a health and wellness company known for its OPTAVIA solution.
Renaissance Holdings amends Schedule 13G: 773,710 shares in MED (MED)
Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have filed an amended Schedule 13G/A, disclosing beneficial ownership of 773,710 shares of MEDIFAST INC (MED) common stock, representing 6.96% of the class. The filing, signed on May 14, 2026, indicates that Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation hold sole voting and dispositive power over these shares. Certain funds managed by Renaissance also have the right to receive dividends and proceeds from the sale of these securities.
Medifast director Scott Schlackman buys $62,950 in company stock
Medifast director Scott Schlackman recently purchased $62,950 worth of company common stock through two separate transactions earlier this month. Following these acquisitions, Schlackman now directly holds over 30,000 shares of Medifast common stock. The stock is currently trading at $12.57, up significantly year-to-date, and appears undervalued according to InvestingPro.
Medifast director Scott Schlackman buys $62,950 in company stock
Medifast director Scott Schlackman recently purchased 5,000 shares of company stock in two transactions totaling $62,950, increasing his direct holdings to over 30,500 shares. These purchases occurred as Medifast's stock has risen 17.7% year-to-date, despite a weak financial health rating. The company also recently reported mixed Q1 2026 earnings, beating EPS estimates but missing revenue projections.
Medifast (MED) director Scott Schlackman adds 5,000 shares in open-market buys
Medifast Inc. director Scott Schlackman purchased a total of 5,000 shares of the company's common stock through two open-market transactions. He bought 2,500 shares on May 8, 2026, at $12.65 per share and another 2,500 shares on May 11, 2026, at $12.53 per share. Following these purchases, Schlackman directly owns 30,548.707 shares of Medifast Common Stock.
Medifast Announces Quarterly Dividend
Medifast (NYSE: MED) has announced a quarterly cash dividend of $1.65 per share, payable on November 7, 2023, to stockholders of record as of September 19, 2023. The company expects to maintain this quarterly dividend program, though future declarations are subject to the discretion of its Board of Directors based on relevant factors. Medifast, known for its OPTAVIA® lifestyle solution, is a leader in the U.S. weight management industry.
Medifast Q1 Loss Narrower Than Expected, Revenues Decline Y/Y
Medifast (MED) reported its first-quarter 2026 results, with both top and bottom lines surpassing Zacks Consensus Estimates despite year-over-year declines in revenues and a wider loss per share. The company faced challenges from a significant reduction in active earning OPTAVIA coaches and the growing popularity of GLP-1 weight-loss medications, though average revenue per coach improved. Medifast provided a cautious outlook for Q2 and full-year 2026, anticipating profitability improvements starting in Q4 2026 with a new product launch.
Why is Medifast stock surging despite weak Q1? $30M cost-cut plan
The article discusses why Medifast (MED) stock is surging despite a weak first quarter. The company announced a $30 million cost-cut plan, which seems to be the primary driver for the positive investor sentiment. This move suggests a focus on improving financial health amidst challenging market conditions.
Medifast Q1 Loss Narrower Than Expected, Revenues Decline Y/Y
Medifast (MED) reported its first-quarter 2026 results, with both earnings and revenues surpassing Zacks Consensus Estimates, though both metrics declined year-over-year. The company posted a narrower-than-expected loss per share and revenues of $76 million, despite a significant reduction in active earning OPTAVIA coaches, attributed to client acquisition challenges and the rise of GLP-1 weight-loss medications. Despite a decline in the coach count, average revenue per active earning coach increased, and Medifast projects profitability to improve in the fourth quarter of 2026 and beyond with a new product line launch.
Medifast, Inc. (NYSE:MED) Q1 2026 Earnings Call Transcript
Medifast (NYSE:MED) reported its Q1 2026 earnings, beating expectations with an EPS of $-0.19 against an expected $-0.55. The company highlighted its strategic shift towards the metabolic health market, showing early signs of stabilization with sequential quarterly revenue growth and increased coach productivity despite a decline in active coaches. Medifast is implementing cost-saving measures and plans to launch a new comprehensive metabolic system to drive future growth and reattain profitability by Q4 2026.
Medifast (NYSE:MED) Issues Q2 2026 Earnings Guidance
Medifast (NYSE:MED) has issued its Q2 2026 earnings guidance, projecting EPS between -1.00 and -0.50 and revenue between $60M and $80M, both below consensus estimates. The company also updated its full-year 2026 EPS guidance to -2.75 to -1.55. Shares dropped after the announcement, with analysts holding a "Reduce" rating and a target price of $12.00, while institutional investors hold approximately 95.5% of the stock.
Q1 2026 revenue down 34.3% as Medifast (NYSE: MED) guides to full-year loss
Medifast reported a significant decline in its Q1 2026 revenue, which fell 34.3% to $76.0 million, leading to a net loss of $2.1 million. The company attributes this to a 44.9% decrease in active earning coaches, partly due to the rapid adoption of GLP-1 weight-loss medications. Medifast forecasts continued losses for the remainder of 2026, with full-year revenue expected between $270 million and $300 million and a loss per share of $1.55 to $2.75, as it transitions to a metabolic health strategy.
Medifast Inc reports results for the quarter ended March 31 - Earnings Summary
Medifast Inc. (MED) has released its earnings summary for the quarter that ended on March 31. This report provides key financial performance indicators for the company during that period. The full details are available through Thomson Reuters.
Medifast Q1 2026 Earnings Call Insights and Outlook
Medifast reported Q1 2026 revenue of $76 million, a 34.3% year-over-year decline, but also its first sequential revenue growth in three years, signaling stabilization. Despite a 44.9% decline in active coaches, average revenue per coach increased by 19.2%. The company aims for over $30 million in cost savings and plans a new metabolic system launch in July, expecting a return to profitability by Q4 2026 and sustained growth into 2027.
Medifast, Inc. 2026 Q1 - Results - Earnings Call Presentation (NYSE:MED) 2026-05-04
Medifast, Inc. (NYSE:MED) released its Q1 2026 earnings results, with an EPS of -$0.19, beating estimates by $0.33. The company reported revenue of $76.04 million, which was a 34.29% year-over-year decrease but still beat expectations by $6.84 million. The earnings call presentation was published on May 4, 2026.
Medifast (MED) Q1 2026 Earnings Transcript
Medifast (MED) reported Q1 2026 earnings with a 34.3% revenue decline year-over-year but achieved its first sequential revenue growth in three years. The company is transitioning to a metabolic health-focused model, driven by increased coach productivity and new product launches, anticipating a return to profitability by Q4 2026. CEO Daniel R. Chard announced his resignation effective June 1, 2026, but will remain as chairman.
Medifast (NYSE:MED) Q1 Loss Narrower Than Feared as Coach Productivity Improves
Medifast (NYSE:MED) reported a narrower-than-expected Q1 2026 loss of $0.19 per share, beating analyst estimates, with revenue also exceeding expectations at $76.0 million. Despite a significant drop in active earning coaches due to GLP-1 medications, the company saw a 19.2% increase in average revenue per coach and improved efficiencies. While the Q1 results were positive, the full-year guidance suggests a deeper loss than anticipated by analysts, indicating continued challenges in its transformation toward metabolic health.
Medifast (NYSE:MED) Releases FY 2026 Earnings Guidance
Medifast (NYSE:MED) has released its FY 2026 earnings guidance, projecting EPS between -2.75 and -1.55, and revenue between $270M and $300M. The company also updated its Q2 2026 EPS guidance to -1.00 to -0.50. Despite these projections, Medifast recently surpassed quarterly expectations, reporting EPS of ($0.19) and revenue of $76.04M, leading to a 3% dip in share price after the guidance update.
Medifast (NYSE: MED) Q1 2026 sales drop as coach count shrinks
Medifast (NYSE: MED) reported a significant decline in Q1 2026 revenue, falling 34.3% to $76.0 million, and a wider net loss of $2.1 million, compared to $0.8 million a year prior. This downturn is primarily attributed to a sharp reduction in active earning OPTAVIA coaches, from 25,400 to 14,000, influenced in part by the increasing adoption of GLP-1 weight loss medications. Despite the financial setbacks, Medifast maintains a strong balance sheet with $168.9 million in cash and investments and no debt, as it pivots its strategy towards holistic metabolic health and new product innovations.
Medifast: Q1 Earnings Snapshot
Medifast Inc. (MED) reported a first-quarter loss of $2.1 million, or 19 cents per share, with revenue reaching $76 million. The weight-loss company anticipates revenue between $60 million and $80 million for the current quarter and projects a full-year loss of $1.75 to $1.55 per share on revenue ranging from $270 million to $300 million.
Medifast Announces First Quarter 2026 Financial Results
Medifast announced its first-quarter 2026 financial results, reporting revenue of $76.0 million and a net loss of $2.1 million. Despite a decrease in overall revenue and active earning coaches compared to Q1 2025, the company highlighted a second consecutive quarter of year-over-year coach productivity growth and strong engagement, attributing revenue decline primarily to fewer active earning coaches and broader operating environment challenges, including the rise of GLP-1 medications. Medifast provided a forward-looking outlook, expecting second-quarter 2026 revenue between $60 million and $80 million and full-year revenue between $270 million and $300 million, as it continues its metabolic health strategy.
Medifast: Q1 Earnings Snapshot
Medifast Inc. (MED) reported a first-quarter loss of $2.1 million, or 19 cents per share, on revenue of $76 million. The weight-loss company expects revenue for the current quarter to be between $60 million and $80 million, and a full-year loss of $1.75 to $1.55 per share with revenue ranging from $270 million to $300 million.
Medifast (MED) Q1 Earnings: What To Expect
Medifast (MED) is set to report its Q1 earnings, with analysts expecting a 40.2% year-on-year revenue decline. The company has a history of missing Wall Street's revenue estimates. Despite this, positive investor sentiment in the consumer staples segment has seen Medifast's share price rise 3.7% in the last month, nearing its average analyst price target of $12.
Medifast Inc expected to post a loss of 52 cents a share - Earnings Preview
Medifast Inc (MED) is expected to report an upcoming earnings loss of 52 cents per share. This financial forecast is provided by Refinitiv and is part of an earnings preview.
Medifast (NYSE:MED) - Stock Analysis
Medifast (NYSE:MED) is a health and wellness company with a market cap of US$113.1m, currently trading at US$10.87, which analysts consider 9.4% undervalued with a target of US$12.00. The company is strategically expanding into solutions for GLP-1 users and personalized wellness, aiming to improve customer retention and stabilize margins, despite an forecast decline in earnings by an average of 24.7% per year for the next three years. Recent news indicates a focus on metabolic health initiatives, enhanced insurance access for its programs, and adjustments to analyst price targets reflecting fine-tuned expectations.
Medifast to Announce Financial Results for the First Quarter Ended March 31, 2026
Medifast (NYSE: MED) will announce its financial results for the first quarter ended March 31, 2026, on Monday, May 4, 2026, after market close. The company will host a conference call at 4:30 p.m. ET on the same day to discuss the results, featuring CEO Dan Chard, President Nick Johnson, and CFO Jim Maloney. The call will be accessible via webcast on Medifast's investor relations website and a telephonic playback will be available for a week following the event.
Medifast Inc stock (US58470S1024): Why Google Discover changes matter more now
Google's 2026 Discover Core Update is significantly changing how investors access information on Medifast Inc (US58470S1024) stock, prioritizing proactive, personalized, and mobile-first financial content. This update delivers tailored insights directly to users' Google app feeds based on their past activity, before they even search. The article argues this shift is crucial for retail investors to stay ahead in tracking Medifast's performance and market trends, especially given the company's coach-driven business model and the mobile-centric nature of modern stock research.
Medifast to Announce Financial Results for the First Quarter Ended March 31, 2026
Medifast (NYSE: MED) will announce its financial results for the first quarter ended March 31, 2026, on Monday, May 4, 2026, after market close. The company will host a conference call at 4:30 p.m. ET (May 4, 2026) with key executives to discuss the results, which will be accessible via their investor relations website and archived online. A telephonic playback will also be available for a week following the call.
Medifast (MED) to Release Earnings on Monday
Medifast (NYSE:MED) is scheduled to release its Q1 2026 earnings after market close on Monday, April 27th, with analysts expecting a loss of ($0.55) per share on $69.20 million in revenue. The company recently posted Q4 results where it beat analyst estimates, reporting ($0.55) EPS for the quarter. Several analysts have adjusted their ratings and price targets for Medifast, with a consensus "Reduce" rating and a $12.00 target price.
Medifast Survey Finds Majority of U.S. Adults Trying to Lose Weight Agree Lifestyle Changes Are Essential – Even with Weight Loss Medications
A Medifast-commissioned survey revealed that a majority of U.S. adults trying to lose weight believe lifestyle changes are essential, even when using weight loss medications. Key findings indicate that 65% think medications are more effective with lifestyle changes, and 73% would still commit to healthy eating, 72% to exercise, and 55% to quality sleep. Medifast emphasizes its holistic OPTAVIA® solution, which combines habit-based programs, coach guidance, and support for those incorporating GLP-1 medications.
How Medifast Inc (MED) Affects Rotational Strategy Timing
This article analyzes Medifast Inc (MED) and its impact on rotational strategy timing, based on AI models. It highlights stable neutral readings in shorter horizons potentially easing a long-term weak bias, an exceptional short setup with a 41.0:1 risk-reward ratio, and neutral sentiment. The article also outlines three distinct trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, along with multi-timeframe signal analysis.
Medifast, Inc. (MED) stock price, news, quote and history
This Yahoo Finance page provides a comprehensive overview of Medifast, Inc. (MED) stock, including its current price, historical data, financial performance, and analyst insights. The company, a health and wellness provider, offers various weight loss and management products, trading at $10.05 with a -1.57% change as of market open. The page also offers profitability metrics and comparisons with similar companies in the Personal Services industry.
Medifast's Latest Product Development: Major Driver for Recovery?
Medifast (MED) is shifting its business strategy from traditional weight loss to a metabolic health approach, introducing new products designed to optimize metabolic function and reduce visceral fat. This strategic pivot, driven by a significant market opportunity and increasing patient abandonment of GLP-1 medications, is expected to improve profitability by Q4 2026 and continue growing into 2027. Despite a recent decline in stock performance, the company anticipates a return to growth and profitability through its science-driven product pipeline, with analysts recommending alternative stocks like Mama's Creations (MAMA), US Foods Holding Corporation (USFD), and B&G Foods (BGS) for consideration.
Medifast's New Product Pipeline: Key Catalyst for Comeback?
Medifast is shifting its focus from traditional weight loss to a broader metabolic health strategy, targeting a large underserved market. The company is developing a new product line leveraging its metabolic synchronization science, designed to reduce visceral fat and improve body composition, especially for individuals transitioning off GLP-1 treatments. Medifast anticipates profitability improvements starting in Q4 2026, with continued earnings growth thereafter, driven by this science-led product pipeline.
Medifast's Latest Product Development: Major Driver for Recovery?
Medifast (MED) is shifting its business model from traditional weight loss to a comprehensive metabolic health approach, introducing new products based on metabolic science aimed at reducing visceral fat and preserving lean muscle. This strategic shift is driven by the growing market opportunity in metabolic health, particularly among individuals discontinuing GLP-1 medications, with the company anticipating improved profitability by Q4 2026 and sustained growth into 2027.
Medifast (NYSE: MED) outlines metabolic shift, board changes in 2026 proxy
Medifast (NYSE: MED) has detailed its strategic shift towards holistic metabolic health, highlighted by its Metabolic Synchronization platform, and announced board changes in its 2026 proxy statement. The company is asking stockholders to vote on director elections, auditor ratification, executive pay, and an amended share incentive plan at its May 19, 2026 meeting. Daniel Chard will transition from Chairman and CEO to non-executive Chairman on June 1, 2026, separating the roles.
Medifast Inc stock: Why it's down but still drawing investor eyes
Medifast Inc stock has declined due to shifting consumer trends and competition, but recent insider buying, including a significant purchase by the CEO, suggests potential undervaluation. The company's coach-guided weight loss model and strategic investments in digital tools and corporate wellness aim to drive a rebound, making its upcoming Q1 2026 earnings report a critical event for investors. Despite market volatility and competition from GLP-1 drugs, analysts view Medifast with cautious optimism, noting its potential for returns if demand recovers.
Medifast Inc stock: Why it's down but still drawing investor eyes
Medifast Inc stock has experienced significant declines due to shifting consumer trends and increased competition, yet insider buying and upcoming Q1 2026 earnings are drawing investor attention. The company's unique coach-guided weight loss model through its OPTAVIA brand, coupled with strategic moves like digital tool investment and corporate wellness expansion, positions it as a potential value play in the consolidating North American weight management sector. Despite risks from sustained demand weakness and competition from drug-based solutions, market analysts maintain a cautious yet opportunity-laden outlook, contingent on upcoming earnings performance.
Medifast, Inc. Trade Ideas — LS:889384
This article compiles several trade ideas and analyses for Medifast, Inc. (MED), trading under LS:889384. Discussions range from the stock being oversold with a low RSI and attractive valuation metrics after a Q3 earnings miss, to technical analyses considering resistance levels, MACD, and stochastic indicators for potential long or short positions. The company's Q3 financial highlights and revised 2019 guidance are also provided.
MED SEC Filings - Medifast 10-K, 10-Q, 8-K Forms
This page provides access to Medifast (MED) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms, offering comprehensive insights into the company's financial condition, governance, and strategic developments. Recent filings detail director equity compensation, executive transitions, and the results of the 2025 Annual Meeting, where shareholders approved an additional 550,000 shares for equity awards and re-elected directors. Stock Titan enhances these filings with AI-powered summaries to help investors understand complex regulatory disclosures efficiently.
Medifast Stock Performance & Outlook 2026: Revenue Down 37.7% Annually - News and Statistics
Medifast has experienced a significant decline, with its stock price falling 27.7% to $9.88 and revenue decreasing 37.7% annually over the past three years, indicating weak demand and low business quality. Despite this, its forward EV-to-EBITDA multiple suggests the market still has favorable expectations. The report concludes that Medifast is expected to underperform due to its low margin of safety, making it vulnerable to market changes.
Medifast Inc Stock: Weight Management Leader Faces Evolving Consumer Trends and Competitive Pressure
Medifast Inc, known for its OPTAVIA brand, operates in the weight management sector with a coach-driven model. The company faces competitive pressures from new digital disruptors and GLP-1 drugs while leveraging its personalized coaching and pre-packaged meal replacements. For North American investors, Medifast offers exposure to the wellness sector with a potentially stable dividend policy, though regulatory scrutiny and coach attrition remain key risks.
Medifast CEO Buys $178K in Company Stock
Medifast CEO Daniel Chard purchased 17,678 shares of company stock for $178,724 on March 20th, a move seen as a vote of confidence amid a declining stock price. The investment suggests Chard believes the company is undervalued and has strong future prospects. Investors are now watching for the company's next earnings report in early May for further insights.
Medifast Inc Stock: Weight Management Leader Faces Evolving Consumer Trends and Competitive Pressure
Medifast Inc, through its OPTAVIA brand, is a key player in the weight management industry, utilizing a coach-driven model and pre-packaged meal replacements. While it faces competition from digital disruptors and GLP-1 drugs, its personalized approach and strong North American market presence have historically driven growth. The company’s financial performance is characterized by high margins and a focus on recurring revenue from its coach network, while strategic initiatives involve continuous product innovation and technology integration to maintain its competitive edge.
Medifast (MED) chairman Chard buys $178k in shares
Medifast (MED) Chairman and CEO Daniel R. Chard reported purchasing $178,724 worth of company shares on March 20, 2026, when the stock was near its 52-week low and considered undervalued by InvestingPro. This purchase occurred despite recent financial challenges reported by Medifast, including an EPS miss in Q4 2025 and a lowered price target from Stephens due to margin pressures and market adoption of GLP-1 drugs. Chard also disposed of shares to cover tax obligations related to restricted stock units.
Medifast (NYSE:MED) CEO Acquires $178,724.58 in Stock
Medifast CEO Daniel Chard recently acquired 17,678 shares of the company's stock, valued at $178,724.58, on March 20th, marking a significant increase in his direct ownership. Despite the recent stock purchase and a beat on Q4 2025 earnings estimates, the company faces negative margins, return on equity, and has issued negative guidance for FY 2026 and Q1 2026. Analysts currently rate Medifast as "Reduce" with an average price target of $12.00, while institutional investors hold a substantial portion of the shares.
Medifast (NYSE: MED) CFO gets stock awards, uses shares for taxes
Medifast CFO James P. Maloney received routine equity compensation, including 34,344 restricted stock units and 1,014 performance-based shares. To cover associated tax withholdings, shares totaling 4,624 at various prices were automatically withheld. Following these transactions, Maloney directly holds 73,033 shares of Medifast common stock.
Vanguard affiliate realignment shows 0% stake in Medifast (MED)
The Vanguard Group has filed an amended Schedule 13G/A, indicating a 0% beneficial ownership in Medifast (MED) common stock following an internal realignment effective January 12, 2026. This realignment disaggregated certain Vanguard subsidiaries' holdings, meaning these entities will now report their beneficial ownership separately in accordance with SEC guidelines. The filing, signed by Ashley Grim, Head of Global Fund Administration, emphasizes that this change reflects a reporting attribution adjustment rather than a market transaction by Medifast.
